Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Change in Accured Expenses (2016 - 2025)

Editas Medicine (EDIT) has disclosed Change in Accured Expenses for 11 consecutive years, with -$543000.0 as the latest value for Q3 2025.

  • Quarterly Change in Accured Expenses fell 153.5% to -$543000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $8.5 million through Sep 2025, up 327.56% year-over-year, with the annual reading at $1.3 million for FY2024, 29.39% down from the prior year.
  • Change in Accured Expenses for Q3 2025 was -$543000.0 at Editas Medicine, down from $578000.0 in the prior quarter.
  • The five-year high for Change in Accured Expenses was $6.8 million in Q4 2024, with the low at -$9.6 million in Q1 2021.
  • Average Change in Accured Expenses over 5 years is $35166.7, with a median of $531500.0 recorded in 2022.
  • The sharpest move saw Change in Accured Expenses crashed 284.18% in 2021, then surged 368.55% in 2023.
  • Over 5 years, Change in Accured Expenses stood at $5.3 million in 2021, then crashed by 90.8% to $485000.0 in 2022, then skyrocketed by 266.6% to $1.8 million in 2023, then surged by 282.11% to $6.8 million in 2024, then plummeted by 107.99% to -$543000.0 in 2025.
  • According to Business Quant data, Change in Accured Expenses over the past three periods came in at -$543000.0, $578000.0, and $1.7 million for Q3 2025, Q2 2025, and Q1 2025 respectively.